KIN - Kindred Biosciences announces positive results for antibody therapy

Kindred Biosciences (KIN) announces positive results in a pilot field effectiveness study for an antibody therapy in canine inflammatory bowel disease.Over a four-week treatment period, the monoclonal antibody against tumour necrosis factor alpha (anti-TNF? antibody), was assessed in a randomized, blinded, placebo-controlled study for efficacy and safety in ten dogs with IBD.The primary effectiveness variable was the reduction in Canine Inflammatory Bowel Disease Activity Index score, which was assessed at screening, and days 0, 7, 14, 21, and 28.A 75% of the anti-TNF? group achieved complete remission (? 75% reduction in average post-dose CIBDAI score from baseline), compared to 17% in the placebo group.The treatment effect was early-onset and durable, with 75% of the anti-TNF? treated dogs compared to 17% in the placebo group showing complete remission at day seven, the first post-dose visit.A 50% of the anti-TNF? treated dogs achieved a 100% reduction of CIBDAI score from baseline and

For further details see:

Kindred Biosciences announces positive results for antibody therapy